Major depressive disorder is one of the leading causes of disability worldwide, and a substantial proportion of patients do not achieve adequate improvement with conventional antidepressant treatments. Cannabidiol (CBD), a non-intoxicating cannabinoid derived from Cannabis sativa, has shown potential anxiolytic, anti-inflammatory, and neurobiological effects that may be relevant for depressive disorders.The ANANDA trial is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety, and tolerability of full-spectrum cannabidiol oil as an adjunctive treatment in adults with treatment-resistant major depressive disorder.A total of 120 participants will be randomly assigned to receive either full-spectrum cannabidiol oil or placebo for 12 weeks while maintaining stable antidepressant treatment. Clinical assessments of depressive symptoms, anxiety, sleep quality, perceived stress, and adverse effects will be performed at baseline, Week 4, and Week 12. Blood samples will be collected at baseline and after 12 weeks to investigate inflammatory and neuroendocrine biomarkers.The primary objective is to evaluate changes in depressive symptoms after 12 weeks of treatment. Secondary objectives include the assessment of anxiety, sleep quality, perceived stress, biological markers, safety, and tolerability.The findings of this study may contribute to the development of new therapeutic approaches for treatment-resistant depression and provide additional evidence regarding the clinical use of cannabidiol in psychiatric disorders.

Study to evaluate the efficacy and tolerability of a simethicone-containing evacuating solution for colorectal cancer screening colonoscopy.

The treatment decisions, assessment schedule, and study procedures in this research will adhere to the routine clinical practice of each participating center. The specifics are as follows:Treatment Decisions: Treatment will be administered in accordance with the officially approved drug label for Ivonescimab by the National Medical Products Administration (NMPA) and the latest domestic and international guidelines. Eligible patients meeting the inclusion criteria will receive first-line Ivonescimab monotherapy until disease progression or unacceptable toxicity occurs. The recommended dosage of Ivonescimab is 20 mg/kg administered intravenously every 3 weeks. Each infusion should be completed over 60 minutes (± 10 minutes). For patients who cannot tolerate the 60-minute (± 10 minutes) infusion, the duration may be extended to a maximum of 120 minutes (± 10 minutes). Dosing may be interrupted or permanently discontinued based on individual patient safety and tolerability; however, dose increases or reductions are not recommended. Dose modification and management of adverse events will follow the drug label and relevant guidelines. Any other concomitant supportive care or medications during the study period should be based on a comprehensive patient assessment, excluding contraindications explicitly stated in the label or guidelines, and administered according to the routine clinical practice of each center.Assessment Plan: The timing, items, and frequency of all assessments, including tumor imaging evaluations and laboratory tests, will follow the routine clinical practice of each participating center.Study Procedures: This study does not mandate protocol-defined study visits. A suggested visit schedule is provided solely to facilitate unified data collection and management.Investigators will prospectively and continuously collect clinical data for all patients who provide signed informed consent and meet the eligibility criteria via an Electronic Data Capture (EDC) system until a study endpoint event occurs or the study concludes.

ACHIEVE is a prospective observational cohort and biobank study of patients with suspected or diagnosed central vascular graft or endograft infection. The study also includes patients undergoing elective central vascular graft or endograft implantation and healthy blood donor controls. Participants undergo longitudinal clinical data collection and biospecimen sampling. The study aims to characterize clinical outcomes, host immune responses, inflammatory biomarkers, pathogen-related factors, and novel microbiological diagnostic methods, including microbial cell-free DNA sequencing, in vascular graft and endograft infections.

This is a prospective, randomized controlled clinical trial designed to compare the safety and effectiveness of robot-assisted transradial cerebral angiography versus manual operation performed by experienced neurosurgeons. The study will be conducted at the Department of Neurosurgery, The First Hospital of Hebei Medical University, with a total sample size of 156 participants.Why is this study being done? Cerebral angiography is a key diagnostic procedure for cerebrovascular diseases, such as stroke, aneurysm, and vascular malformation. Traditionally, it is performed manually by interventional physicians, who are exposed to significant radiation during the procedure. Robot-assisted technology offers a potential solution by allowing doctors to operate from a separate, shielded room, which could greatly reduce occupational radiation exposure. This study aims to verify whether robot-assisted transradial cerebral angiography is non-inferior to the standard manual approach in terms of safety and clinical success, while providing additional benefits for both patients and physicians.Who can participate?We plan to enroll 156 adult patients (aged 18-80 years) who meet the following criteria:Stable vital signs and eligible for routine cerebral angiography Suspected intracranial vascular lesions or need for evaluation of intracranial mass blood supply, confirmed by CTA/MRA Positive Allen's test and adequate radial artery diameter (assessed by ultrasound) Able to provide informed consent Patients will be excluded if they have contrast allergy, require emergency angiography, have severe organ dysfunction, are pregnant or breastfeeding, or refuse robot-assisted procedures.What will happen during the study?After providing informed consent, eligible participants will be randomly assigned to one of two groups in a 1:1 ratio:Robot-assisted group: Cerebral angiography will be performed using a dedicated cerebrovascular interventional robot system, with the physician operating from a remote, radiation-free room.Manual control group: Cerebral angiography will be performed by experienced neurosurgeons using the standard manual technique.During the procedure, researchers will record key metrics including:Technical and clinical success rates of angiography Total procedure time and radiation exposure for both patients and physicians Incidence of perioperative and postoperative complications (e.g., vascular injury, hematoma, contrast reaction) Participants will be followed until hospital discharge or their next scheduled interventional treatment, during which all adverse events and complications will be carefully documented.What are the potential risks and benefits?Potential benefits:Participants will receive high-standard cerebral angiography care, either via robot-assisted or manual operation, both of which are clinically approved methods.The study results may help establish robot-assisted technology as a safe, effective alternative for cerebrovascular diagnosis, which could reduce physician radiation exposure and improve procedural precision in the future.Potential risks:Standard risks associated with cerebral angiography, including contrast allergy, vascular spasm, dissection, or puncture-site hematoma.Very low risk of device-related complications, such as unintended robot movement, which will be mitigated by strict operator training and safety protocols.How will the data be analyzed? All data will be analyzed using SAS 9.4 or later software. The primary analysis will use a non-inferiority design to compare the clinical success rate between the two groups. Secondary analyses will compare complication rates, radiation exposure, procedure duration, patient comfort, and surgeon satisfaction. All statistical tests will be two-sided, with a p-value ≤ 0.05 considered statistically significant.This study is designed to provide robust evidence on the safety and efficacy of robot-assisted transradial cerebral angiography, with the ultimate goal of advancing minimally invasive cerebrovascular care and protecting healthcare workers from occupational radiation hazards.

The purpose of this study is to determine if Eltrombopag is as effective of a treatment for patients with newly diagnosed Immune Thrombocytopenia (ITP) when compared to standard treatment.

This phase II trial studies how well giving radiation therapy together with gemcitabine hydrochloride and cisplatin work in treating patients with locally advanced squamous cell carcinoma of the vulva.